Twitter

The first insurance-reimbursed K.O.S treatment carried out in Saudi Arabia

Chordate Medical Holding AB (publ) ("Chordate") announces that the first privately insured chronic rhinitis patient in Saudi Arabia has now been treated with the company's K.O.S treatment. This is the first time that the K.O.S treatment has been reimbursed by the health insurance company BUPA ARABIA in Saudi Arabia. The announcement means that all private hospitals and clinics in Saudi Arabia that have access to the code nationally can start treating patients who have been waiting.

"The result of this extensive project to establish sales on the private side and finally get the confirmation that the first treatment has been reimbursed, is a very important milestone for Chordate and for our hard-working distribution partner in Saudi Arabia. This is very satisfying", says Anders Weilandt, CEO of Chordate.

As the company announced in November 2020, private health insurance companies in Saudi Arabia approved the insurance code that can be used by private care providers in the country when treating with K.O.S for chronic rhinitis. Now, the first insurance-reimbursed K.O.S treatment has been completed.

"One of our strategic goals is to prove the market opportunity in well-selected markets to enable expansion and growth and to be able to attract buyers of the company. Saudi Arabia is one of the markets selected and the news that the first privately insured patient now has been treated with K.O.S is a major step towards that goal."

Information:
This disclosure contains information that Chordate Medical Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person below, on December 8th, 2021, at 14:50 a.m. CET.

For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277
e-mail: anders.weilandt@chordate.com

The following documents can be retrieved from beQuoted
The-first-insurance-reimbursed-K-O-S-treatment-carried-out-i.pdf

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more at https://www.chordate.com/en/

The-first-insurance-reimbursed-K-O-S-treatment-carried-out-i.pdf

Chordate Medical signs new joint venture agreement with Nanos Medical in Shanghai

Chordate Medical (publ) ("Chordate" or "the Company") and the Chinese medtech company Nanos Medical have entered into a renewed joint venture agreement governing the cooperation of the jointly owned company Changyong Medical Technology Co. which will market Chordate's treatment method for rhinitis, chronic nasal congestion, in the Chinese market. Nanos Medical, which invests all working capital in the jointly owned company, estimates the schedule for obtaining the market license to be at least 16 months.

Chordate and Nanos Medical started a joint venture in 2018 and then formed a jointly owned company in Shanghai with the intention of marketing the K.O.S technology in the Chinese market. Nanos Medical owns 2/3 of this company, Changyong Medical Technology Co., and is the party that finances marketing and sales, Chordate will for its 1/3 submit the Chinese patents when product registration is in place.

In August, Chordate received a prepaid order for two new-generation K.O.S. machines which has since been delivered to Changyong Medical Technology Co. Ltd. The K.O.S machines are used in the work to obtain a national market permit for Chordate's technology for rhinitis treatment. The registration work is ongoing.

"This means that we still have a capital-strong partner in China who believes in and invests in the K.O.S treatment for rhinitis. Nanos Medical is said to be the Number One actor on the Ear/Nose/Throat-market in China", says Anders Weilandt, CEO of Chordate Medical.

Information:
This disclosure contains information that Chordate Medical Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person below, on December 6th, 2021, at 15:00 a.m. CET.

For more information, please contact:
Anders Weilandt
Managing Director
Cell: +46 733-874277
e-mail: anders.weilandt@chordate.com

The following documents can be retrieved from beQuoted
Chordate-Medical-signs-new-joint-venture-agreement-with-Nano.pdf

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more at www.chordate.com

Chordate-Medical-signs-new-joint-venture-agreement-with-Nano.pdf

Chordate Medical Holding AB (Publ.) launches pre-study for FDA market approval in the United States

Chordate Medical has made a strategic decision to initiate a pre-study to apply for marketing authorization for the K.O.S treatment for chronic migraine with the US Food and Drug Administration, FDA. The work is carried out in collaboration with a reputable American consulting company. The pre-study will begin immediately and can be expected to be completed within the first quarter of 2022, when a decision on the choice of strategy can be made.

Chordate's initial analysis indicates that this is a so-called DeNovo application, and the company has focused the project on tentatively moving forward to the submission of a complete application during the second half of 2022.

"As a natural step after the CE mark came into place in May earlier this year, we now want to move forward with market permits in the US as well. This is a longer project, but an important step to take in the strategy of building company value. This ambition to procure a US market permit does not mean that we have changed the model on how we build our proof of market. However, our assessment is that an approved DeNovo application in the long run gives us a broader set of options and makes Chordate more interesting for the medtech industry in general", says Anders Weilandt, CEO of Chordate.

"The project is to first carry out a pre-study to select the appropriate strategy, then a pre-submission step to understand the perspective of the FDA on a tentative submission, and finally the formal application. An important issue is to find out what level of scientific evidence the FDA wants to see in an application for acceptance. This will take time and need a clear focus on our part."

Information:

This disclosure contains information that Chordate Medical Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person below, on October 13th, 2021, at 10:00 a.m. CET.

Anders Weilandt
Managing Director
Cell: +46 733-874277
e-mail: anders.weilandt@chordate.com

The following documents can be retrieved from beQuoted
Chordate-Medical-Holding-AB-Publ-launches-pre-study-for-FD.pdf

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more athttps://www.chordate.com/en/

Chordate-Medical-Holding-AB-Publ-launches-pre-study-for-FD.pdf

Communiqué from the Extraordinary General Meeting of Chordate Medical Holding AB (Publ.) on October 5th, 2021

Chordate Medical Holding AB (Publ.) ("Chordate" or "the Company") held an Extraordinary General Meeting on October 5th, 2021, whereby the following main resolutions were made.

In order to counteract the spread of covid-19, the meeting was conducted only by postal vote without physical participation.

Determination of fees to the board and election of the board

The EGM determined that the board fee shall amount to a maximum of SEK 400,000 with the following distribution. The Chairman shall be remunerated with SEK 160,000 and other members who are not employees of the Company shall be remunerated with SEK 80,000 each.

Re-election of the board members Henrik Rammer, Tommy Hedberg, Gunilla Lundmark, and new election of Caroline Lundgren Brandberg.

Long-term incentive program 2021

The EGM agreed to establish a long-term incentive program through a resolution on a directed issue of a maximum of 5,500,000 warrants, entailing an increase in the share capital upon full exercise by a maximum of SEK 1,375,000, in accordance with the Board's proposal. The issue is carried out with the deviation from the shareholders' preferential rights, in accordance with what has been previously communicated, with the purposes that through the introduction of an incentive program, current and future employees and consultants in the Company will be able to become long-term shareholders and work for, and take part of, a positive value development of the share in the Company during the period covered by the proposed program, and that the Company will be able to retain and recruit competent and committed staff.

Full terms and conditions for the above-mentioned proposals are available in full on the company's website: https://www.chordate.com/investor-relations/bolagsstyrning/bolagsstaemma/

Nomination Committee for the 2022 Annual General Meeting

The EGM resolved to establish a Nomination Committee prior to the 2022 Annual General Meeting. The Nomination Committee consists of representatives of the four largest shareholders, namely Isak Brandberg AB (12.1%), HAWOC Investment AB (10.4%), Sifonen (9.1%) and Tommy Hedberg (5.4%).

This disclosure was submitted for publication, through the contact person below, on October 5th, 2021, at 13:30 pm CET.

For more information, please contact:
Anders Weilandt, CEO
e-mail: anders.weilandt@chordate.com
Cell: +46 733-874277

The following documents can be retrieved from beQuoted
Communique-from-the-Extraordinary-General-Meeting-of-Chordat.pdf

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more athttps://www.chordate.com/en/

Communique-from-the-Extraordinary-General-Meeting-of-Chordat.pdf

Quarterly report brought forward in Chordate Medical Holding AB (publ)

Chordate Medical Holding AB (publ) ("Chordate" or "the Company") hereby announces that the Board has today decided to bring forward the company's report for Q3 2021 to give owners and stakeholders in the outstanding warrant TO7 the opportunity to view the quarterly report before trading in the option ends October 27, 2021, and before October 29, 2021, which is the last day for redemption of TO7. The report for the period July-September 2021 will be published on October 25 2021 instead of November 19 as previously communicated.

The company's financial calendar has been updated and can be found at https://www.chordate.com/en/investor-relations/financial-calendar/

This disclosure was submitted for publication, through the contact person below, on September 23rd, 2021, at 16:00 pm CET.

For more information, please contact:

Anders Weilandt
Managing Director
Cell: +46 733-874277, e-mail: anders.weilandt@chordate.com

The following documents can be retrieved from beQuoted
Chordate-Tidigarelagd-delarsrapport-Q3-21-EN.pdf

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more athttps://www.chordate.com/en/

Chordate-Tidigarelagd-delarsrapport-Q3-21-EN.pdf

Notice of Extraordinary General Meeting of Chordate Medical Holding AB (publ)

N.B. The English text is an in-house translated summary of the original Swedish text and should only be construed as a brief notification service to non-domestic shareholders. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

The shareholders of Chordate Medical Holding AB (publ) are hereby summoned to the Extraordinary General Meeting on October 5th, 2021.

Matters of the Extraordinary General Meeting are listed below. The notice in its entirety and postal voting form will be made available in English on the company website.

  1. Election of chairman
  2. Establishment and approval of the ballot paper
  3. Selection of one or two adjusters
  4. Examination of whether the Extraordinary General Meeting has been duly convened
  5. Approval of agenda
  6. Determination of fees to the board
  7. Election of a board member
  8. The Board's proposal for a long-term incentive program 2021
  9. Establishment of a nomination committee

For more information about the full Notice of Extraordinary General Meeting, please read the Swedish version (or the English version, when made available on the company website), or contact the company.

This disclosure was submitted for publication, through the contact person below, on September 20th, 2021, at 14:30 am CET.

For more information, please contact:

Anders Weilandt, VD
anders.weilandt@chordate.com
Phone: +46 (0) 733 87 42 77

The following documents can be retrieved from beQuoted
Notice-of-Extraordinary-General-Meeting-of-Chordate-Medical-.pdf

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more at https://www.chordate.com/en/

Notice-of-Extraordinary-General-Meeting-of-Chordate-Medical-.pdf

The Board decides to convene an Extraordinary General Meeting

Chordate Medical Holding AB's (publ) ("Chordate") Board of Directors has today decided to convene an Extraordinary General Meeting. The reason for the Extraordinary General Meeting is to decide on the election of a new Board member, Caroline Lundgren Brandberg, a decision on the establishment of a Nomination Committee and a decision on a new option program for key persons in the company. The formal notice must be published no later than September 21st, where full information on each decision point will be included.

The Board's decision to convene an Extraordinary General Meeting relates to three matters. Shareholders representing more than 50 percent of the ownership propose that Caroline Lundgren Brandberg take a seat on the board. The matter of the Nomination Committee intends to formalize such a review body before the next Annual General Meeting. The option program is intended to give the company the opportunity to be able to attract and retain the right competence in the company.

This disclosure was submitted for publication, through the contact person below, on September 14th 2021 at 16:40 am CET.

For more information, please contact:

Anders Weilandt, VD
anders.weilandt@chordate.com
Phone: +46 (0) 733 87 42 77

The following documents can be retrieved from beQuoted
The-Board-decides-to-convene-an-Extraordinary-General-Meetin.pdf

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more athttps://www.chordate.com/en/

The-Board-decides-to-convene-an-Extraordinary-General-Meetin.pdf

Chordate intends to change trading venue to Nasdaq First North Growth Market

The board of Chordate Medical Holding AB (publ) ("Chordate") has today decided to start the process of changing trading venue to Nasdaq First North Growth Market in Stockholm. The company's shares are currently traded on NGM Nordic SME.

The Board believes that a change of trading venue for the company's shares to Nasdaq First North Growth Market will increase the knowledge of the company both in Sweden and internationally, making it easier for industrial investors to become shareholders, and have a positive impact on the company's relationships with partners and potential customers.

Overall, a change of trading venue is considered to be positive for Chordate's development and completion of the stated exit strategy. Nasdaq First North Growth Market is Nasdaq's European growth market, with the same legal status as NGM Nordic SME. Shareholders in Chordate will not have to take any action in the event of a change of trading venue.

We are grateful for the cooperation and the good dialogue between the company and NGM during the period the company's share has been listed on NGM Nordic SME.

Advisor
Västra Hamnen Corporate Finance AB is Chordate's advisor regarding the planned list change and Certified Adviser.
Wistrand Advokatbyrå AB is Chordate's legal advisor.

This disclosure was submitted for publication, through the contact person below, on September 14th, 2021, at 16:30 am CET.

For more information, please contact:

Anders Weilandt, VD
anders.weilandt@chordate.com
Phone: +46 (0) 733 87 42 77

The following documents can be retrieved from beQuoted
Chordate-intends-to-change-trading-venue-to-Nasdaq.pdf

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more at https://www.chordate.com/en/

Chordate-intends-to-change-trading-venue-to-Nasdaq.pdf

Chordate secures bridge loans of SEK 7,125 million from five owners

Chordate Medical Holding AB's (publ) ("Chordate") has today procured bridge loans of SEK 7,125 million, in five different agreements, from the main owners Magnus Brandberg, Hawoc Invest AB, Sifonen AB, Bevaclean AB and related board member Tommy Hedberg. The purpose of the bridge loans is to strengthen the company's liquidity and working capital for the upcoming redemption period of warrant TO7. The loans can be offset against TO7, which is due to be redeemed in October 2021, but has a maturity of 12 months and is admitted at market rate.

"We have chosen to take advantage of a standing offer of support before the TO7 redemption period and believe that the time is now appropriate to strengthen our cash holdings. We are incredibly grateful for the support shown by the long-term owners – which is important in this type of enterprise," says Anders Weilandt, CEO of Chordate.

Information:
This disclosure contains information that Chordate Medical Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person below, on September 7, 2021 at 08:15 a.m. CET.

Anders Weilandt, CEO
anders.weilandt@chordate.com
Telefon: +46 (0) 733 87 42 77

The following documents can be retrieved from beQuoted
Chordate-bridge-loans eng.pdf

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more athttps://www.chordate.com/en/

Chordate-bridge-loans eng.pdf

The first migraine patients undergo K.O.S treatment in Sweden

Clinics in Malmö and Solna in Sweden have now started treating migraine patients with Chordate Medical Holding AB's (publ) ("Chordate") K.O.S treatment. It is the first time K.O.S. treatment has been used to treat chronic migraines in regular clinical practice.

"The clinics see a great interest and many people seek the treatment spontaneously. Within a few days, our collaborating clinic in Gothenburg will also be able to offer K.O.S. treatment for chronic migraines.

"The work to establish sales in our selected markets in Europe continues, and the fact that we now have patients undergoing the treatment is very satisfactory," says Anders Weilandt, CEO of Chordate.

Chordate received CE marking of the K.O.S method for treatment of chronic migraines in May 2021. The CE marking means that K.O.S meets the clinical efficacy and safety requirements for chronic migraines in the European Medical Devices Directive. This approval allows Chordate to commercialize migraine treatment freely within the EU, and now the first patients have started treatment in Sweden.

 

 

 

This disclosure was submitted for publication, through the contact person below, on August 19th 2021 at 11.50 am CET.

 

For further information, please contact:

Anders Weilandt, CEO
anders.weilandt@chordate.com
Telefon: +46 (0) 733 87 42 77

The following documents can be retrieved from beQuoted
the-first-migraine-patients-2021-08-19-eng.pdf

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more athttps://www.chordate.com/en/

the-first-migraine-patients-2021-08-19-eng.pdf

Chordate Medical Holding AB (publ) är ett medicintekniskt bolag som har utvecklat, patenterat och CE-märkt Ozilia® Migraine (tidigare K.O.S), en neuromodulerande och läkemedelsfri behandlingsteknik mot kronisk migrän och kronisk rinit. Behandlingen har bevisad effekt enligt en nyligen genomförd kliniskt studie och marknadsförs på utvalda marknader i EU och Mellanöstern. Chordate Medical är noterat på Nasdaq First North Growth Market Stockholm (kortnamn: CMH).

Bolagets Certified Adviser på Nasdaq First North Growth Market Stockholm är Vator Securities AB.

Pressmeddelanden

Chordate Medical AB

c/o Regus, Kistagången 20B
SE-164 40 Kista
Sweden

Integritet

Twitter